Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · August 02, 2012

Four Cycles of Adjuvant Therapy for Low-Risk Breast Cancer

Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes
J. Clin. Oncol 2012 Jul 23;[EPub Ahead of Print], LN Shulman, CT Cirrincione, DA Berry, HP Becker, EA Perez, R O’Regan, S Martino, JN Atkins, E Mayer, CJ Schneider, G Kimmick, L Norton, H Muss, EP Winer, C Hudis

Further Reading